Source: International Congress 2018 – Tests and trends in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Cheng (Taichung, Taiwan), C. Tu (Taichung, Taiwan), B. Wu (Taichung, Taiwan), C. Chen (Taichung, Taiwan), W. Chen (Taichung, Taiwan), T. Hsia (Taichung, Taiwan), W. Liao (Taichung, Taiwan), C. Chen (Taichung, Taiwan), W. Hsu (Taichung, Taiwan). Clinical predictors of the effectiveness of tiotropium in adults with symptomatic asthma: the real-life data. 3946

Member's Comments

No comment yet.

Related content which might interest you: Clinical phenotypes of asthmatics who require long-term use of tiotropium for asthma control: a real-world study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Safety of formoterol in children and adolescents: experience from asthma clinical trials Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Influence of patient baseline characteristics and concomitant medication on outcomes in long-term trials of COPD: Analysis of the UPLIFT® trial Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Evaluating cardiac safety of tiotropium in patients with COPD: Combined analysis of Holter-ECG data from four trials Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Physician assessment of asthma control in patients receiving omalizumab in a real-world setting Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Clinical and functional effectiveness of roflumilast in severe COPD patients Source: Annual Congress 2013 –Modern approach to various clinical settings Year: 2013 Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Safety of formoterol in asthma clinical trials: an update Source: Eur Respir J 2014; 43: 103-114 Year: 2004 Cardiac events among patients with CV comorbidities: Pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Efficacy of the using budesonide/formoterol in patients with bronchial asthma (BA): the study of routine clinical practice Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Cost effectiveness of omalizumab in Swedish asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Prevalence and clinical predictors of inhaler discordance in COPD: an observational study Source: Virtual Congress 2020 – Prognosis and integrated management of COPD Year: 2020 Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials Source: Eur Respir J 2006; 28: Suppl. 50, 175s Year: 2006 Clinical benefits and safety of long term treatment with montelukast (M) in patients with mild-to-moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003 Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium Source: ERJ Open Res, 5 (4) 00253-2018; 10.1183/23120541.00253-2018 Year: 2019 Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013